Newton H B, Junck L, Bromberg J, Page M A, Greenberg H S
Department of Neurology, University of Michigan Hospitals, Ann Horbor 48109-0316.
Neurology. 1990 Nov;40(11):1743-6. doi: 10.1212/wnl.40.11.1743.
The Brain Tumor Study Group has shown procarbazine (PCB) to be as effective an adjuvant treatment as 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). We treated 35 patients with recurrent malignant astrocytomas after radiation and nitrosourea failure with successive courses of PCB 150 mg/m2/d for 28 days every 8 weeks. After 2 courses, 2 patients had complete responses, 7 had partial responses, 11 had stable disease, and 15 had progression. Significantly more patients receiving PCB had complete or partial responses or stable disease than a similar group of patients in a previous trial who received intra-arterial (IA) cisplatin (DDP). There is a significant advantage in time to disease progression for those receiving PCB compared with those receiving IA diaziquone (AZQ). Our results suggest that PCB is a more effective 2nd agent than IA DDP or AZQ following radiation and nitrosourea failure.
脑肿瘤研究组已表明丙卡巴肼（PCB）作为辅助治疗与1,3-双（2-氯乙基）-1-亚硝基脲（BCNU）同样有效。我们对35例放疗和亚硝基脲治疗失败后的复发性恶性星形细胞瘤患者，每8周给予连续28天、剂量为150 mg/m²/天的PCB治疗。2个疗程后，2例患者完全缓解，7例部分缓解，11例病情稳定，15例病情进展。与先前一项接受动脉内（IA）顺铂（DDP）治疗的类似患者组相比，接受PCB治疗的患者中完全或部分缓解或病情稳定的患者明显更多。与接受IA二氮嗪醌（AZQ）治疗的患者相比，接受PCB治疗的患者在疾病进展时间方面有显著优势。我们的结果表明，在放疗和亚硝基脲治疗失败后，PCB作为二线药物比IA DDP或AZQ更有效。
